Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announces that it has commenced a pilot sales and marketing program with Cardinal Health for its uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's catalogue of offerings to the urology market.
The uroNIRS 2000 provides a real-time, non-invasive evaluation of the bladder function during voiding to aid in the diagnosis of bladder outlet obstruction. The product is approved for sale in the U.S.
New analysis sheds light on cancer incidence and mortality trends in the UK